Cargando…
Depletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF)
BACKGROUND: Psoriasis and inflammatory bowel disease (IBD) are chronic inflammatory diseases sharing similar pathogenic pathways. Intestinal microbial changes such as a decrease of bakers’ yeast Saccharomyces cerevisiae have been reported in IBD, suggesting the presence of a gut-skin axis. OBJECTIVE...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423625/ https://www.ncbi.nlm.nih.gov/pubmed/28486503 http://dx.doi.org/10.1371/journal.pone.0176955 |
_version_ | 1783234983445397504 |
---|---|
author | Eppinga, Hester Thio, H. Bing Schreurs, Marco W. J. Blakaj, Blerdi Tahitu, Ruena I. Konstantinov, Sergey R. Peppelenbosch, Maikel P. Fuhler, Gwenny M. |
author_facet | Eppinga, Hester Thio, H. Bing Schreurs, Marco W. J. Blakaj, Blerdi Tahitu, Ruena I. Konstantinov, Sergey R. Peppelenbosch, Maikel P. Fuhler, Gwenny M. |
author_sort | Eppinga, Hester |
collection | PubMed |
description | BACKGROUND: Psoriasis and inflammatory bowel disease (IBD) are chronic inflammatory diseases sharing similar pathogenic pathways. Intestinal microbial changes such as a decrease of bakers’ yeast Saccharomyces cerevisiae have been reported in IBD, suggesting the presence of a gut-skin axis. OBJECTIVE: To investigate whether the S. cerevisiae abundance was altered in psoriasis patients versus healthy controls, and whether dimethylfumarate (DMF) interacted with this yeast. METHODS: Using qPCR, faecal samples were compared between psoriasis patients without DMF (n = 30), psoriasis patients with DMF (n = 28), and healthy controls (n = 32). RESULTS: Faecal S. cerevisiae abundance was decreased in psoriasis compared to healthy controls (p<0.001). Interestingly, DMF use raised S. cerevisiae levels (p<0.001). Gastrointestinal adverse-effects of DMF were correlated with a higher S. cerevisiae abundance (p = 0.010). In vitro, a direct effect of DMF on S. cerevisiae growth was observed. In addition, anti-Saccharomyces cerevisiae antibodies were not elevated in psoriasis. CONCLUSION: The abundance of baker’s yeast S. cerevisiae is decreased in psoriasis patients, but appears to be restored upon DMF use. S. cerevisiae is generally classified as a yeast with beneficial immunomodulatory properties, but may also be involved in the occurrence of DMF’s gastrointestinal adverse-effects. Potentially, DMF might be a new therapy for IBD. |
format | Online Article Text |
id | pubmed-5423625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-54236252017-05-15 Depletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF) Eppinga, Hester Thio, H. Bing Schreurs, Marco W. J. Blakaj, Blerdi Tahitu, Ruena I. Konstantinov, Sergey R. Peppelenbosch, Maikel P. Fuhler, Gwenny M. PLoS One Research Article BACKGROUND: Psoriasis and inflammatory bowel disease (IBD) are chronic inflammatory diseases sharing similar pathogenic pathways. Intestinal microbial changes such as a decrease of bakers’ yeast Saccharomyces cerevisiae have been reported in IBD, suggesting the presence of a gut-skin axis. OBJECTIVE: To investigate whether the S. cerevisiae abundance was altered in psoriasis patients versus healthy controls, and whether dimethylfumarate (DMF) interacted with this yeast. METHODS: Using qPCR, faecal samples were compared between psoriasis patients without DMF (n = 30), psoriasis patients with DMF (n = 28), and healthy controls (n = 32). RESULTS: Faecal S. cerevisiae abundance was decreased in psoriasis compared to healthy controls (p<0.001). Interestingly, DMF use raised S. cerevisiae levels (p<0.001). Gastrointestinal adverse-effects of DMF were correlated with a higher S. cerevisiae abundance (p = 0.010). In vitro, a direct effect of DMF on S. cerevisiae growth was observed. In addition, anti-Saccharomyces cerevisiae antibodies were not elevated in psoriasis. CONCLUSION: The abundance of baker’s yeast S. cerevisiae is decreased in psoriasis patients, but appears to be restored upon DMF use. S. cerevisiae is generally classified as a yeast with beneficial immunomodulatory properties, but may also be involved in the occurrence of DMF’s gastrointestinal adverse-effects. Potentially, DMF might be a new therapy for IBD. Public Library of Science 2017-05-09 /pmc/articles/PMC5423625/ /pubmed/28486503 http://dx.doi.org/10.1371/journal.pone.0176955 Text en © 2017 Eppinga et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Eppinga, Hester Thio, H. Bing Schreurs, Marco W. J. Blakaj, Blerdi Tahitu, Ruena I. Konstantinov, Sergey R. Peppelenbosch, Maikel P. Fuhler, Gwenny M. Depletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF) |
title | Depletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF) |
title_full | Depletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF) |
title_fullStr | Depletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF) |
title_full_unstemmed | Depletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF) |
title_short | Depletion of Saccharomyces cerevisiae in psoriasis patients, restored by Dimethylfumarate therapy (DMF) |
title_sort | depletion of saccharomyces cerevisiae in psoriasis patients, restored by dimethylfumarate therapy (dmf) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423625/ https://www.ncbi.nlm.nih.gov/pubmed/28486503 http://dx.doi.org/10.1371/journal.pone.0176955 |
work_keys_str_mv | AT eppingahester depletionofsaccharomycescerevisiaeinpsoriasispatientsrestoredbydimethylfumaratetherapydmf AT thiohbing depletionofsaccharomycescerevisiaeinpsoriasispatientsrestoredbydimethylfumaratetherapydmf AT schreursmarcowj depletionofsaccharomycescerevisiaeinpsoriasispatientsrestoredbydimethylfumaratetherapydmf AT blakajblerdi depletionofsaccharomycescerevisiaeinpsoriasispatientsrestoredbydimethylfumaratetherapydmf AT tahituruenai depletionofsaccharomycescerevisiaeinpsoriasispatientsrestoredbydimethylfumaratetherapydmf AT konstantinovsergeyr depletionofsaccharomycescerevisiaeinpsoriasispatientsrestoredbydimethylfumaratetherapydmf AT peppelenboschmaikelp depletionofsaccharomycescerevisiaeinpsoriasispatientsrestoredbydimethylfumaratetherapydmf AT fuhlergwennym depletionofsaccharomycescerevisiaeinpsoriasispatientsrestoredbydimethylfumaratetherapydmf |